Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
about
Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy.NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).Current strategies in chemoradiation for esophageal cancer.Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancerEarly response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients.Imaging strategies in the management of oesophageal cancer: what's the role of MRI?A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers.The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinomaShould preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation.Tumor SUVmax Normalized to Liver Uptake on (18)F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.PET/CT and hepatic radiation injury in esophageal cancer patients.18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.Role of positron emission tomography in the (re-)staging of oesophageal cancer.(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET.Oesophageal cancer: assessment of response and follow upThe role of positron emission tomography in esophageal cancer.The 100 most cited articles investigating the radiological staging of oesophageal and junctional cancer: a bibliometric analysis.Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer.Esophageal cancer: current and emerging therapy modalities.Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction.Role of barium esophagography in patients with locally advanced esophageal cancer: evaluation of response to neoadjuvant chemoradiotherapy.PET imaging for Treatment Response in CancerMonitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer.Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological CorrelationIdentification of Metabolic Biomarkers Using Serial 18F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian CancerTiming and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis.Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus.
P2860
Q30524018-B5265DD0-465E-4D15-83BC-D26B4D1B2A8CQ33356751-8A0E36DF-2603-4895-8FB7-5D7EE9CC31A7Q33820782-FA9DBE7B-D7E6-4AC4-A346-C13EAE21A642Q33866015-6B82E313-5959-41FC-B3A0-4C292A7FCC35Q34104159-84568E24-96DF-472A-A863-1475A5571A4CQ34164634-B8B60C8E-8714-46A8-A879-2CEA863F9BFAQ34390923-0312E316-63B8-4CA1-8D7E-29AF0977A0B2Q34521659-C8A41486-3A06-4540-85AA-69461C3CAD7CQ34583617-E1FFE08F-890A-4D82-97D6-FB6CCBBA2031Q34961992-6A0F25C0-3293-4F52-892A-5F2AC2504990Q34978457-8F69352B-18D2-4344-88C3-57634F246D3EQ35583933-F30F6044-6C85-4D8C-B6EE-5818CB53F574Q35769322-C1833FF6-4C73-4D64-893C-1D3A41FA864AQ35824736-3D77179D-9D48-4CC8-A7F0-C8C07C7EA7D3Q35830542-9542CF4E-AD0E-4E45-8479-E64CC85A0737Q35922472-0E6E7161-82E5-405E-9147-EE2596139524Q36022348-3512A3A3-96A5-4FEF-AE78-32060BEB6472Q36064592-7441513D-F0F9-4EC6-A8D7-73703029E553Q36278127-273A944D-12C3-4978-A7BD-DF7E90A159CAQ36295210-EF3B5D60-925D-4E34-BADF-2158527B5851Q36328330-974F9A15-5128-42C6-88F6-ECA08CA47BACQ36427789-CE5EB3CE-DAAF-401C-9CDF-02749136FD7AQ36510702-86188F58-2D58-45A3-A39B-D95739ECC61FQ36611842-32F68BC4-0882-4656-93C4-B62669F285BFQ36643836-06F19077-CB2A-4FE7-A2C7-70AE16C8A13DQ36963796-3FD6A60F-6733-427B-85FB-EC4B2FBF87B5Q37072481-67D9DE87-02A5-4022-B593-F8C293BE5FDFQ37116282-65FA92F8-0C4F-4B68-9FB9-F21055528B30Q37121648-F7F457AA-C435-4C7E-924B-96010C024539Q37154079-0D88F761-AFB2-489D-BE09-63479823DBECQ37256825-08681EC7-74ED-4C7C-8DFC-E1CF3520A02EQ37338260-D11E61FC-2508-45CE-A866-4BC74522A29DQ37402817-CE60CAE6-5CE2-4B32-B540-719C066118DAQ37465205-413DD83B-CF0D-4F9F-8FD8-71C337221276Q37681293-24769810-05D8-420D-8116-309C997219FFQ37712152-7939A137-3566-490E-BA00-46FBD3D89EAFQ37715868-81637F29-1679-4C4A-AC56-5EAFDA0002F1Q37717566-7D681BB2-D258-42F5-9640-234A66E958A2Q37984273-01680681-9EE3-4A70-9A3F-F1BF7EA654BAQ38034225-8AED8E6F-697E-476A-9B0A-C1BEAA95E20F
P2860
Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Positron emission tomography f ...... y advanced oesophageal cancer.
@en
Positron emission tomography f ...... y advanced oesophageal cancer.
@nl
type
label
Positron emission tomography f ...... y advanced oesophageal cancer.
@en
Positron emission tomography f ...... y advanced oesophageal cancer.
@nl
prefLabel
Positron emission tomography f ...... y advanced oesophageal cancer.
@en
Positron emission tomography f ...... y advanced oesophageal cancer.
@nl
P2093
P356
P1433
P1476
Positron emission tomography f ...... y advanced oesophageal cancer.
@en
P2093
D Van Raemdonck
E Van Cutsem
J P Cambier
K Haustermans
L Mortelmans
P304
P356
10.1093/ANNONC/MDF081
P577
2002-03-01T00:00:00Z